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Objectives. This study was performed to compare the safety and
efficacy of intravenous 2% dodecafluoropentane (DDFP) emulsion
(EchoGen) with that of active control (sonicated human albumin
[Albunex]) for left ventricular (LV) cavity opacification in adult
patients with a suboptimal echocardiogram.
Background. The development of new fluorocarbon-based echo-
cardiographic contrast agents such as DDFP has allowed opaci-
fication of the left ventricle after peripheral venous injection. We
hypothesized that DDFP was clinically superior to the Food and
Drug Administration–approved active control.
Methods. This was a Phase III, multicenter, single-blind, active
controlled trial. Sequential intravenous injections of active con-
trol and DDFP were given 30 min apart to 254 patients with a
suboptimal echocardiogram, defined as one in which the endocar-
dial borders were not visible in at least two segments in either the
apical two- or four-chamber views. Studies were interpreted in
blinded manner by two readers and the investigators.
Results. Full or intermediate LV cavity opacification was more
frequently observed after DDFP than after active control (78% vs.
31% for reader A; 69% vs. 34% for reader B; 83% vs. 55% for the
investigators, p < 0.0001). LV cavity opacification scores were
higher with DDFP (2.0 to 2.5 vs. 1.1 to 1.5, p < 0.0001).
Endocardial border delineation was improved by DDFP in 88% of
patients versus 45% with active control (p < 0.001). Similar
improvement was seen for duration of contrast effect, salvage of
suboptimal echocardiograms, diagnostic confidence and potential
to affect patient management. There was no difference between
agents in the number of patients with adverse events attributed to
the test agent (9% for DDFP vs. 6% for active control, p 5 0.92).
Conclusions. This Phase III multicenter trial demonstrates that
DDFP is superior to sonicated human albumin for LV cavity
opacification, endocardial border definition, duration of effect,
salvage of suboptimal echocardiograms, diagnostic confidence
and potential to influence patient management. The two agents
had similar safety profiles.
(J Am Coll Cardiol 1998;32:230–6)
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Echocardiography is the most widely used cardiac imaging
modality in the United States, with .5 million studies per-
formed annually (1). Its most common clinical indication is to
assess global and regional left ventricular (LV) function (2), a
task that depends on the ability to distinguish the endocardial
border from the LV blood pool. Unfortunately, endocardial
border definition is often limited by poor acoustic windows or
endocardial “dropout” in the apical views (3,4). This problem
has fueled efforts to develop transpulmonary contrast agents
that can opacify the LV cavity after intravenous injection,
thereby accurately identifying the endocardial surface and
enhancing the ability to measure LV size and function (5,6).
The first transpulmonary agent to be Food and Drug
Administration (FDA)–approved for LV opacification was
Albunex, air-filled microbubbles of sonicated 5% human albu-
min (7–9). Despite its early promise, this agent has not been
widely used in echocardiography, in part because the air-filled
microbubbles often do not persist in the circulation long
enough for adequate imaging. Newer contrast agents use
fluorocarbon gases, which, owing to their low diffusivity and
blood solubility, persist longer in the circulation (10). A 2%
dodecafluoropentane (DDFP) emulsion (EchoGen) has been
developed as a novel phase-shift colloidal contrast agent
containing liquid droplets of DDFP that convert to gaseous
microbubbles after hypobaric activation (11). After intrave-
nous administration, the microbubbles rapidly distribute in the
vascular space (distribution half-life ,90 s) and are subse-
quently eliminated from the lungs, without metabolism,
through expired air. The half-life of DDFP is 2 min in blood
and 10 to 16 min in expired air (12).
The present study was performed to compare the efficacy of
intravenous DDFP with that of active control (Albunex) for
LV cavity opacification in adult patients with a suboptimal
echocardiogram. A secondary objective was to compare the
clinical utility of the two agents for facilitating diagnosis and
management. Finally, we compared the safety of these two
echocardiographic contrast agents.
Methods
Study design. This Phase III, multicenter, single-blind,
active-controlled trial was performed at 18 centers in the
United States. The active control agent used in this study was
sonicated 5% human albumin (Albunex, Mallinckrodt Medi-
cal), an FDA-approved device for LV opacification during
echocardiography (9). To be enrolled in the study, patients had
to have a suboptimal echocardiogram, defined as one in which
the endocardial borders were not visible in at least two
segments in either the apical two- or four-chamber views.
Exclusion criteria included 1) known history of anaphylaxis or
drug allergy requiring treatment; 2) premenopausal patients
who were lactating, pregnant or potentially pregnant; 3) any
investigational drug within 7 days; 4) history of alcohol or drug
abuse; 5) clinically significant pulmonary disease manifested by
active wheezing, hypoxia or breathlessness; 6) history of sleep
apnea and obesity (.130% of ideal body weight); 7) serious or
life-threatening condition; 8) New York Heart Association
functional class III or IV heart failure; 9) unstable neurologic
disease; 10) known or suspected right to left shunt; 11)
unstable angina; 12) recent myocardial infarction (,6
months); or 13) serious cardiac arrhythmias.
Echocardiography. Written informed consent was ob-
tained in all subjects. A 20-gauge intravenous catheter was
placed in the right antecubital fossa, and the patient was
positioned in the left lateral decubitus position. Vital signs,
pulse oximetry and a 12-lead electrocardiogram (ECG) were
recorded at baseline. A blood sample was obtained and sent to
a core laboratory for complete blood count, serum electrolytes,
liver function tests and renal function tests. Baseline echocar-
diography was performed using commercially available equip-
ment operating at a transmit and receive frequency of
2.5 MHz. Instrument settings, including gain, depth and gray-
level compression, were optimized for each patient and then
held constant for all baseline and postcontrast images. Apical
two- and four-chamber views were required to determine
efficacy; other views were optional. All studies were recorded
on 1⁄2-in. SVHS videotape for subsequent analysis.
After the baseline echocardiogram was recorded, the active
control agent was administered as a bolus injection of 0.22
ml/kg. Repeat echocardiographic images were recorded during
the injection and until contrast effect was no longer visible in
the left ventricle. Blood pressure, heart rate, respiratory rate
and oximetry were measured eight times during the 15 min
after injection. A 12-lead ECG was monitored at 1 to 5 and 6
to 15 minutes after injection. The occurrence of adverse effects
was sought through open-ended interview.
A 30-min washout period was then observed, followed by
administration of 2% DDFP emulsion (0.05 ml/kg). Repeat
echocardiographic images were recorded during the injection
and until contrast effect was no longer visible in the left
ventricular cavity. Blood pressure, heart rate, respiratory rate
and oximetry were measured eight times during the 15 min
after injection. A 12-lead ECG was monitored at 1 to 5 and 6
to 15 min after injection. The occurrence of adverse effects was
sought through open-ended interview. A repeat blood sample
was obtained 1 h after the injection. Each patient was asked to
return 18 to 48 h after the study for a repeat blood sample, vital
signs, pulse oximetry and occurrence of adverse events.
Data analysis. The primary efficacy evaluation was per-
formed by two experienced echocardiographers (A.N.D.,
D.J.S.) who read the studies in randomized order without
knowledge of whether the contrast images were obtained after
DDFP or active control. The blinded readers were specifically
Abbreviations and Acronyms
DDFP 5 dodecafluoropentane
ECG 5 electrocardiogram, electrocardiographic
FDA 5 Food and Drug Administration
LV 5 left ventricular
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trained in grading endocardial border definition and LV
opacification using the scoring system described below. In
addition, the 18 primary investigators graded each echocardio-
gram in an unblinded manner.
Efficacy end points. The efficacy of each contrast echocar-
diographic agent was assessed by means of end points that
were organized into four tiers: 1) technical end points, 2)
anatomic end points, 3) diagnostic end points, and 4) patient
management end points.
Technical end points included the intensity and duration of
contrast enhancement provided by the test agent. The intensity
of LV opacification after contrast administration was graded as
0 5 none; 1 5 faint detectable contrast; 2 5 intermediate
opacification; and 3 5 full opacification. The duration of LV
opacification was measured (by the investigators only) from
the appearance of contrast in the left ventricular until chamber
opacification returned to baseline. In the subset of patients in
whom the contrast agent worsened the image, the contrast
imaging window was calculated as the time that contrast was
present in the chamber minus the time that the image was
degraded.
Anatomic end points included the ability of the test agent to
improve visualization of the endocardial border and salvage a
technically difficult study. Endocardial border definition was
graded in each of 12 myocardial segments in the apical two-
and four-chamber views for both baseline and contrast echo-
cardiograms as 0 5 border not seen; 1 5 faint border
delineation; 2 5 intermediate border delineation; and 3 5
excellent border delineation. An endocardial border delinea-
tion score was calculated as the sum of individual segment
scores divided by 12 (the number of segments). Salvage of a
suboptimal echocardiogram was defined as improvement from
an endocardial border definition score from 0 or 1 in at least
two adjacent segments to a score of 2 or 3 in at least five of six
segments in both the apical two- and four-chamber views.
Facilitation of wall motion assessment by the contrast agent
was graded as yes or no.
Diagnostic end points were chosen to determine whether the
contrast agent assisted in making a final diagnosis. The inves-
tigators and blinded readers were specifically asked whether
the agent 1) provided adequate contrast enhancement of the
blood pool; 2) facilitated endocardial border delineation; 3)
improved the quality of regional wall motion analysis; 4)
provided enhancement of the myocardium; 5) shortened the
time needed to reach a diagnosis (blinded readers only); 6)
improved confidence in the diagnosis and, if yes, to record the
degree of improvement as minimal, low, moderate or signifi-
cant.
Patient management end points evaluated the potential
ability of the test agent to affect a patient’s diagnostic or
therapeutic management strategy. The blinded readers and
investigators were asked whether the contrast agent 1) dis-
closed findings that were not apparent on the baseline echo-
cardiogram; or 2) would have eliminated the need for addi-
tional diagnostic tests or referrals.
Safety end points. Table 1 shows the clinical and laboratory
variables that were measured before and after DDFP. Adverse
events were classified as mild, moderate or severe in intensity.
The relation between adverse events and the test agent was
determined by the investigator to be definitely related, proba-
bly related, possibly related, unknown or not related.
Statistical analysis. Differences between active control and
DDFP in continuous variables, such as LV opacification scores
and endocardial border delineation scores, were compared
using paired t tests. Differences in dichotomous variables were
compared by McNemar’s test. Concordance between observers
was assessed by the Pearson coefficient of correlation. A p
value #0.05 was considered statistically significant.
Results
Demographics. Two hundred fifty-four patients were en-
rolled (21 to 94 years old, mean age 61; 185 men [73%], 69
women [27%]; 221 whites [87%], 30 African-Americans [12%],
3 Asian-Americans [1%]). The diagnosis for which the echo-
cardiogram was obtained was coronary artery disease in 56%
of patients, myocardial infarction in 22%, congestive heart
failure in 16%, valvular heart disease in 19%, arrhythmias in
12%, endocarditis in 1%, pulmonary hypertension in 1% and
pericardial disease in 1%.
LV opacification. Figure 1 shows the percent of patients
with full or intermediate opacification of the LV cavity for each
contrast agent as interpreted by both the reviewers and the
investigators. Full or intermediate LV cavity opacification was
consistently higher for DDFP than for active control (78% vs.
31% for reader A, 69% vs. 34% for reader B, 83% vs. 55% for
the primary investigators, all p , 0.0001).
Figure 2 illustrates the mean LV cavity opacification scores
Table 1. Clinical and Laboratory Variables for Safety Evaluation
Clinical
Variables
ECG
Variables
Laboratory
Variables
Heart rate PR interval CBC
Blood pressure QRS duration Sodium
Respiratory rate QT interval Potassium
Pulse oximetry Rhythm Chloride
Bicarbonate
Glucose
BUN
Creatinine
Calcium
Phosphorus
GGT
ALT
AST
Alkaline phosphatase
Bilirubin, total
Bilirubin, direct
LDH
Total protein
ALT 5 alanine transaminase; AST 5 aspartate transaminase; BUN 5 blood
urea nitrogen; CBC 5 complete blood count; GGT 5 gamma-glutaryl transam-
inase; LDH 5 low density lipoprotein.
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for both contrast agents as determined by the readers and the
investigators. Scores were significantly higher for DDFP than
for active control (2.3 6 0.07 vs. 1.1 6 0.06 for reader A, 2.0 6
0.07 vs. 1.2 6 0.06 for reader B, 2.4 6 0.06 vs. 1.5 6 0.06 for the
investigators, all p , 0.001).
The duration of contrast effect was significantly longer for
DDFP than for active control (4.2 6 0.52 vs. 0.53 6 0.02 min,
p , 0.001). Contrast resulted in worsening of the LV image in
37 patient (15%) after DDFP compared with 48 patients
(19%) after active control (p 5 NS). In these patients, the
contrast imaging window was 134 s with DDFP and 8 s with
active control.
Endocardial border delineation. Compared with baseline
images, endocardial border delineation was improved by
DDFP in 88% of patients versus 45% with active control for
the investigators, 86% versus 58% for reader A and 83%
versus 62% for reader B (all p , 0.001). In the four-chamber
view, endocardial border detection was improved in 86% of
patients with DDFP versus 47% with active control for the
investigators, 83% versus 52% for reader A, and 81% versus
59% for reader B (all p , 0.001). In the two-chamber view,
endocardial border detection was improved in 80% after
DDFP compared with 30% with active control for the investi-
gators, 75% versus 40% for reader A and 79% versus 50% for
reader B (all p , 0.001). Concordance between observers was
good for endocardial border definition (r 5 0.77 between
readers, r 5 0.70 between readers and investigators).
The change in endocardial border delineation score from
baseline to after contrast administration is shown in Figure 3.
Improvement in endocardial border delineation was greater
with DDFP than with active control for blinded reader A
(1.1 6 0.05 vs. 0.3 6 0.03, p , 0.001), blinded reader B (1.2 6
0.06 vs. 0.4 6 0.04, p , 0.001) and the investigators (0.9 6 0.04
vs. 0.2 6 0.02, p , 0.001).
Salvage of suboptimal echocardiograms. Baseline echocar-
diograms improved from suboptimal to diagnostically useful in
51% of patients after DDFP compared with 9% after active
control for the investigators, 54% versus 9% for blinded reader
A and 50% versus 16% for blinded reader B (all p , 0.001).
Assessment of regional wall motion was facilitated by the
contrast agent in 88% of patients after DDFP compared with
37% with active control for the investigators, 85% versus 25%
for blinded reader A and 92% versus 71% for blinded reader
B (all p , 0.001). Figure 4 shows an example of a study that
improved from suboptimal to diagnostically useful with DDFP.
Change in diagnostic confidence. The investigators re-
ported increased confidence in the diagnosis in 76% patients
after DDFP compared with 24% after active control (p ,
0.001). The degree of improvement in diagnostic confidence
was reported as moderate or significant in 80% of cases after
DDFP compared with 43% after active control (p , 0.0001).
Patient management end points. According to the investi-
gators, DDFP added sufficient diagnostic information to influ-
ence management end points in 162 patients (65%) with
DDFP compared with 54 patients (22%) with active control
(p , 0.001). Findings not apparent on the baseline study were
disclosed more frequently by DDFP than by active control
Figure 1. Percent of patients with full or intermediate LV cavity
opacification according to blinded reader A (n 5 250), blinded reader
B (n 5 251) and the investigators (n 5 252). Active control is
represented by hatched bars; DDFP by open bars. *p , 0.0001 for all
comparisons.
Figure 2. Mean LV opacification scores according to blinded readers
and investigators. Symbols as in Figure 1. *p , 0.001 for all compar-
isons.
Figure 3. Change in endocardial border delineation (EBD) scores
from baseline according to blinded readers and investigators. Symbols
as in Figure 1. *p , 0.001 for all comparisons.
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(63% vs. 20%, p , 0.001). Compared with active control,
DDFP could have prevented the need for additional tests or
referrals in 34 patients (19%) versus 12 patients (7%) with
active control (p , 0.001).
Safety. Neither contrast agent resulted in significant
changes in heart rate, blood pressure, respiratory rate, oxygen
saturation, ECG variables or laboratory values.
A total of 89 adverse events were reported in 44 patients
and were considered by the investigators to be related to
DDFP in 23 patients (9%) and to active control in 16 (6%)
(p 5 0.92). Most adverse events were considered to be mild in
severity and resolved spontaneously within 5 min (Table 2).
One patient died during the follow-up period. He was a
57-year old white man with ischemic cardiomyopathy who had
been admitted to the hospital for congestive heart failure 1
week before the study. On the day of study, he was classified as
having functional class II heart failure, and his serum potas-
sium was 3.1 mEq/dl (results returned 3 days later). He had no
adverse effects with either active control or DDFP and re-
turned home. He died suddenly in his sleep ;9 h after the
study. The investigators ruled his death to be unrelated to the
test agents and considered it to be an arrhythmic death
secondary to underlying heart disease and hypokalemia.
Discussion
Evaluation of regional and global LV function is one of the
major clinical indications for echocardiography (13). However,
dropout of the endocardial border in apical views is common
and may preclude assessment of LV function even in patients
with adequate acoustic windows (14). In a recent study of
post–myocardial infarction patients, full visualization of all
endocardial borders in the apical four- and two-chamber views
could only be accomplished in 18 (36%) of 50 patients (9).
Therefore, the ability to adequately define the endocardial
borders by using a transpulmonary contrast agent is an impor-
tant clinical goal in echocardiography (5–10). Although the
active control used in the present study is the only FDA-
approved agent currently available for this indication, its use
has been limited by several factors, including microbubble
destruction and poor persistence in the circulation (15–18).
Our study demonstrates that 2% DDFP emulsion (EchoGen)
is safe and is superior to sonicated 5% human albumin
(Albunex) in intensity of LV opacification, duration of LV
opacification and endocardial border definition. Consequently,
the investigators and blinded readers considered that this new
agent could increase confidence in the diagnosis and poten-
tially improve management strategy.
LV opacification. In a previous large clinical trial of soni-
cated 5% human albumin (9), LV opacification was judged to
be full or intermediate in 74% by independent reviewers. In
the present study, the same agent resulted in intermediate or
full LV opacification in 55% of patients. The reasons for these
different results are unclear; however, several possibilities
exist: 1) The patients in our study tended to be older than those
in the previous trial (mean age 61 vs. 56 years). 2) There may
be unmeasured differences between the patient groups in
clinical variables or echocardiographic technique. For exam-
ple, low cardiac output has been associated with increased
microbubble destruction (18) and was not specifically reported
in either study. Neither study specified acoustic power or other
instrument settings but merely required that they be optimized
for each patient. It is now known that increased acoustic power
and continuous ultrasound delivery enhance destruction of
encapsulated microbubbles (18,19). Despite these consider-
ations, the study design, wherein each patient was used as his
own control and the data were interpreted in blinded manner
Table 2. Adverse Events Attributed to Test Agent
Active Control
(n 5 256)
2% DDFP Emulsion
(n 5 254)
Any adverse event 16 (6.3%) 23 (9.1%)
Abdominal pain 1 (0.4%) 0
Asthma, severe, acute 1 (0.4%) 0
Back pain 0 2 (0.8%)
Cardiovascular 2 (0.8%) 0
Chest pain 1 (0.4%) 1 (0.4%)
Chills 0 1 (0.4%)
Cough 1 (0.4%) 2 (0.8%)
Dizziness 2 (0.8%) 2 (0.8%)
Dry mouth 0 1 (0.4%)
Dyspepsia 0 1 (0.4%)
Eructation 0 1 (0.4%)
Fever 0 1 (0.4%)
Headache 0 2 (0.8%)
Hypertension 1 (0.4%) 0
Nausea 1 (0.4%) 1 (0.4%)
Pain 0 2 (0.8%)
Paresthesia 2 (0.8%) 2 (0.8%)
Respiratory distress 0 1 (0.4%)
Taste alteration 7 (2.7%) 4 (1.6%)
Tongue disorder 0 1 (0.4%)
Urticaria 0 1 (0.4%)
Vasodilation 5 (2.0%) 8 (3.1%)
Data presented are number (%) of patients.
Figure 4. A, Suboptimal baseline echocardiogram showing poor endo-
cardial border definition. Active control did not opacify the LV cavity
(not shown). B, Full LV cavity opacification occurs after DDFP, and
endocardial borders are clearly seen in all segments.
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by independent readers, justifies the conclusion that DDFP is
superior to sonicated 5% human albumin for LV opacification
in humans.
Even in cases where sonicated 5% human albumin fully
opacified the LV cavity, the duration of effect was generally too
short to allow the sonographer to obtain complete images of
the LV from multiple acoustic windows. In contrast, the
prolonged duration of contrast effect with DDFP facilitated
the use of multiple views after a single injection. This pro-
longed duration of effect is largely due to the low diffusivity and
blood solubility of perfluorocarbons relative to air. In addition,
it is conceivable that encapsulated microbubbles, such as
sonicated 5% human albumin, are more prone to destruction
than nonencapsulated agents, such as 2% DDFP emulsion. It
has been noted that air-filled microbubbles demonstrate a
decrease in contrast intensity in the LV cavity during systole;
this has been attributed to microbubble destruction by intra-
cavitary pressure (17,20) and acoustic pressure from the ultra-
sound beam (18). In the present study, these effects were noted
to be much less pronounced with DDFP, suggesting that this
agent may be less subject to microbubble destruction.
Another factor contributing to the longer contrast imaging
window of DDFP was that it caused less attenuation of far-field
structures than did sonicated albumin. The mechanism of this
beneficial effect is thought to be related to lower diffusion rates
of higher molecular weight gases out of the microbubble as
well as their low blood solubility (21). These effects allow
improved contrast effect at lower doses and thereby reduce
attenuation artifacts (21).
Endocardial border definition. Accurate assessment of LV
volumes, ejection fraction and regional wall motion is depen-
dent on adequate visualization of the endocardial surface
(13,14). The present study shows that compared with sonicated
5% human albumin, DDFP provides significantly greater im-
provement in endocardial border delineation in patients with a
suboptimal echocardiogram. Although it is reasonable to as-
sume that this would translate into improved accuracy in
quantitative assessment of LV global and regional wall motion,
we did not compare the contrast-enhanced echocardiograms
with an independent reference standard. However, Hundley et
al. (6) recently showed that 2% DDFP emulsion improved the
accuracy of echocardiographically measured LV volumes, ejec-
tion fraction and regional wall motion scoring compared with
cine magnetic resonance imaging.
Studies in open chest dogs (22,23) have shown that myo-
cardial perfusion defects in the setting of acute myocardial
ischemia can be detected by intravenous injection of DDFP. In
those studies, contrast effect persisted in the myocardium even
after it cleared the LV cavity, suggesting that some of the
microbubbles remained in the myocardium. In the present
study, myocardial contrast enhancement was not consistently
observed with either agent. The reasons for the apparent
differences in myocardial contrast enhancement between the
canine and human studies are not known but are probably
related to the obvious differences between anesthetized, open
chest, mechanically ventilated dogs without intrinsic myocar-
dial or coronary artery disease and conscious patients with a
variety of cardiovascular or systemic diseases. Dogs also re-
ceived a higher dosage of DDFP. In addition, we did not use
second harmonic or intermittent imaging, modalities that have
been shown to greatly augment myocardial enhancement in
humans (19,24–26).
Safety. A previous canine study (22) demonstrated pulmo-
nary hypertension and hypoxemia at high doses (0.7 ml/kg) of
DDFP. Subsequently, a change in the formulation of the
emulsion and the use of hypobaric activation procedures
allowed studies to be done at much lower doses than that used
in our study (0.05 ml/kg). At this dose we found that DDFP
was safe and well tolerated. The side effect profile was similar
to that of sonicated albumin, and there were no significant
changes in vital signs, oximetry, ECG findings or laboratory
values.
Limitations. The present study was performed using fun-
damental imaging at frame rates of at least 30/s. The develop-
ment of second harmonic imaging (18,19,24–26) and ECG
triggering at 1 frame/cycle (19) improved the visualization of
contrast in the LV cavity and myocardium. It is likely that the
scores for both agents would have been higher had these newer
imaging modalities been used. Nevertheless, because most
clinical echocardiography laboratories do not have second
harmonic capability at this time, the results of the present study
are applicable to the current practice of echocardiography.
Conclusions. This Phase III multicenter trial demonstrates
that in patients with a suboptimal echocardiogram, DDFP
emulsion (EchoGen) is superior to sonicated human albumin
(Albunex) for LV cavity opacification, endocardial border
definition, duration of effect, salvage of suboptimal echocar-
diograms, diagnostic confidence and potential to affect patient
management. The two agents had similar safety profiles. These
findings may not be applicable to patients with clinically active
pulmonary disease or obesity-related sleep apnea.
Appendix
Participating Institutions and Investigators for the
EchoGen Contrast Echo Study Group
Clinical centers. University of Texas Southwestern Medical Center,
Dallas, Texas: Paul A. Grayburn, MD, Michael L. Main, MD; Johns
Hopkins University School of Medicine, Baltimore, Maryland: James L.
Weiss, MD, Elizabeth Klodas, MD; Deaconess-Nashoba Hospital, Ayer,
Massachusetts: Terrence C. Hack, MD; Thomas Jefferson University,
Philadelphia, Pennsylvania: Joel S. Raichlen, MD; New England Med-
ical Center, Boston, Massachusetts: Manni A. Vannan, MD; Cleveland
Clinic Foundation, Cleveland, Ohio: Allan L. Klein, MD; Bowman Gray
University Medical Center, Winston-Salem, North Carolina: Dalane W.
Kitzman, MD; Oklahoma Cardiovascular and Hypertension Center,
Oklahoma City, Oklahoma: Steven G. Chrysant, MD, FACC; Veterans
Affair’s Medical Center, East Orange, New Jersey: Jerald L. Cohen, MD;
University of California at Irvine, Orange, California: David Abraham-
son, MD; University of California at San Francisco, San Francisco,
California: Elyse Foster, MD; Washington University Medical School,
235JACC Vol. 32, No. 1 GRAYBURN ET AL.
July 1998:230–6 ECHO CONTRAST WITH ECHOGEN
Saint Louis, Missouri: Julio E. Perez, MD; University of Massachusetts,
Worchester, Massachusetts: Gerard P. Aurigemma, MD; National
Heart, Lung, and Blood Institute, Bethesda, Maryland: Julio A. Panza,
MD; Massachusetts General Hospital, Boston, Massachusetts: Michael
H. Picard, MD; Vanderbilt University, Nashville, Tennessee: Benjamin F.
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